Drug-containing PLA implants and methods of use thereof
The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
1. An implant comprising: a therapeutic drug and a polymer, said polymer comprising polylactic acid (PLA) and optionally polyglycolic acid (PGA) in a PLA:PGA molar ratio between 50:50 and 100:0, wherein said therapeutic drug is present in an amount of about 10%-30% (w/w), wherein the presence of said polymer in said implant extends the release duration of said therapeutic drug in a subject, and wherein said therapeutic drug is risperidone.
2. The implant of claim 1 , wherein said drug is present in an amount of about 30% (w/w).
3. The implant of claim 1 , wherein said drug is present in an amount of about 28% (w/w).
4. The implant of claim 1 , wherein said drug is present in an amount of about 20% (w/w).
5. The implant of claim 1 , wherein said drug is present in an amount of about 15% (w/w).
6. The implant of claim 1 , wherein said drug is present in an amount of about 10% (w/w).
7. The implant of claim 1 , wherein said polymer is a biodegradable polymer.
8. The implant of claim 1 , wherein said polymer is PLGA polymer.
9. The implant of claim 1 , wherein said PLA:PGA molar ratio is 75:25.
10. The implant of claim 1 , wherein said PLA:PGA molar ratio is 80:20.
11. The implant of claim 1 , wherein said PLA:PGA molar ratio is 85:15.
12. The implant of claim 1 , wherein said polymer is present in an amount of about 40-90% (w/w).
13. The implant of claim 1 , wherein said polymer is present in an amount of about 40-70% (w/w).
14. The implant of claim 1 , wherein said polymer is present in an amount of about 35-75% (w/w).
15. The implant of claim 1 , wherein said polymer is present in an amount of about 35% (w/w).
16. The implant of claim 1 , wherein said polymer is present in an amount of about 38% (w/w).
17. The implant of claim 1 , wherein said polymer is present in an amount of about 40% (w/w).
18. The implant of claim 1 , wherein said polymer is present in an amount of about 50% (w/w).
19. The implant of claim 1 , wherein said polymer is present in an amount of about 60% (w/w).
20. The implant of claim 1 , wherein said polymer is present in an amount of about 70% (w/w).
21. The implant of claim 1 , wherein said polymer is present in an amount of about 72% (w/w).
22. The implant of claim 1 , wherein said implant exhibits an inherent viscosity ranging from about 0.2 dl/g to about 0.9 dl/g.
23. The implant of claim 1 , wherein said implant is a subcutaneous implant.
24. An implant comprising: a therapeutic drug and a polymer, said polymer comprising polylactic acid (PLA) and polyglycolic acid (PGA) in a PLA:PGA molar ratio between 75:25 and 85:15, wherein said therapeutic drug is present in an amount of about 10%-60% (w/w) and said polymer is present in an amount of about 40-90% (w/w), wherein the presence of said polymer in said implant extends the release duration of said therapeutic drug in a subject, and wherein said therapeutic drug is risperidone.